Development and preliminary validation of a CD161 immunoscore-based screening method for latent tuberculosis infection in a Chinese training cohort.
Source check: Source checked. Not independent scientific confirmation.
Finding: The deep-learning flow-cytometry immunoscore showed a preliminary CD161-based screening signal; source limitations include post-treatment cases as a proxy and a small all-male evaluation cohort. Published in Microbiology Spectrum.
Technology: Official ASM Methods/Results checked; phase 1 used post-treatment TB cases as a proxy, phase 2 was all-male with 11 IGRA-positive participants and a post-hoc cutoff.
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- Official ASM Methods/Results checked; phase 1 used post-treatment TB cases as a proxy, phase 2 was all-male with 11 IGRA-positive participants and a post-hoc cutoff.
- Test and result
- Official ASM Methods/Results checked; phase 1 used post-treatment TB cases as a proxy, phase 2 was all-male with 11 IGRA-positive participants and a post-hoc cutoff.
- Limitation / still unknown
- External replication and real-world or clinical benefit were not established by the reviewed study.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://journals.asm.org/doi/10.1128/spectrum.01118-26
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.